Grazoprevir

證據等級: L5

預測適應症: 10 個

Grazoprevir: From Hepatitis C to HIV Infectious Disease

One-Sentence Summary

Grazoprevir is an HCV NS3/4A protease inhibitor marketed as part of the fixed-dose combination Zepatier® (grazoprevir + elbasvir), used for chronic hepatitis C virus (HCV) genotype 1, 4, and 6 infection. TxGNN predicts a 99.73% score for "HIV infectious disease," but on review, all supporting clinical trials and literature describe treating HCV in patients who are co-infected with HIV — not treating HIV itself. This is very likely a database co-occurrence artifact rather than a genuine pharmacological signal, and the evidence pack itself flags this rationale explicitly.

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis C virus (HCV) genotype 1, 4, 6 infection — as the protease-inhibitor component of Zepatier® (grazoprevir + elbasvir). (Not present in the structured `original_indications` field; derived from consistent evidence across trials/literature in this pack.)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.73%
Evidence Level	L5 (model prediction only; no study directly treats HIV with grazoprevir)
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed formal MOA data for grazoprevir was flagged as a data gap in this evidence pack. However, the evidence itself (trial descriptions and literature abstracts) consistently identifies grazoprevir as an HCV NS3/4A protease inhibitor, co-formulated with the NS5A inhibitor elbasvir under the brand Zepatier®, used to achieve sustained virologic response (SVR) in chronic HCV infection.

Critically, this mechanism has no known relevance to HIV. HIV requires inhibition of its own protease, reverse transcriptase, or integrase enzymes — none of which are structurally related to HCV NS3/4A protease. Every single clinical trial and literature record returned for this candidate describes treating HCV in patients who happen to also carry HIV (HIV/HCV co-infection populations), evaluating HCV cure rates (SVR12), liver fibrosis, cardiovascular risk, or drug-drug interactions with antiretrovirals. None evaluate grazoprevir as a treatment for HIV itself, and no viral suppression or CD4/viral-load endpoint for HIV is reported anywhere in this evidence set.

Conclusion of this section: the prediction is not mechanistically or clinically supported. It most plausibly reflects a graph-embedding artifact caused by the frequent co-occurrence of "grazoprevir" and "HIV" in trial metadata for HCV/HIV co-infected cohorts, rather than a true repurposing signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02105662	Phase 3	Completed	218	C-EDGE CO-INFECTION: GZR+EBR for HCV GT1/4/6 in HIV/HCV co-infected, treatment-naïve subjects — evaluates HCV SVR12, not HIV outcomes.
NCT01717326	Phase 2	Completed	573	C-WORTHY: GZR+EBR±RBV for HCV; HIV/HCV co-infected arm included, primary endpoint is HCV SVR12.
NCT02252016	Phase 3	Completed	159	GZR+EBR for HCV GT1/4/6 in patients with inherited blood disorders, with/without HIV co-infection.
NCT02785666	Phase 3	Completed	150	Swiss HCVree Trial: "treat, counsel, cure" strategy for HCV in HIV-positive MSM; HIV itself not a treatment target.
NCT02057003	N/A	Unknown	1000	HEPAVIR cohort: real-world efficacy/tolerability of DAA regimens for HCV in HIV/HCV co-infected patients.
NCT02600325	Phase 3	Completed	80	DAHHS-2: GZR+EBR for acute HCV genotype 1/4 in HIV-positive individuals.
NCT02897596	Phase 3	Unknown	62	GZR/EBR for early chronic HCV GT1/4 in HIV co-infected patients (8 vs 12 weeks).
NCT03037151	Phase 4	Unknown	100	Safety/fibrosis improvement with GZR+EBR for HCV GT1/6, cirrhotic, with or without HIV.
NCT03098121	Phase 4	Completed	40	GZR+EBR for HCV GT1 in PWID/MSM with HIV co-infection, prior peg-IFN/RBV experienced.
NCT03823911	Phase 4	Completed	87	Cardiovascular outcomes after HCV eradication in HIV/HCV co-infected vs HIV mono-infected controls — not an HIV efficacy trial.

Every trial above treats HCV in an HIV-positive population; none treats HIV as the target disease.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26423374	2015	RCT	The Lancet HIV	C-EDGE CO-INFECTION: GZR+EBR efficacy/safety for HCV in HIV/HCV co-infected patients.
25467560	2015	RCT (Phase 2)	Lancet	C-WORTHY: 8 vs 12 weeks GZR+EBR±RBV for HCV GT1 mono- and HIV/HCV co-infection.
28689442	2017	Review	Expert Opin Drug Metab Toxicol	Reviews drug-drug interactions between DAAs (incl. grazoprevir) and antiretrovirals in HIV patients being treated for HCV.
30745392	2019	PK study	Antimicrob Agents Chemother	PK interactions of elbasvir/grazoprevir with HIV protease inhibitors (ritonavir, atazanavir, lopinavir, darunavir).
30541077	2019	DDI study	J Antimicrob Chemother	Interaction assessment between elbasvir/grazoprevir and HIV integrase inhibitors (raltegravir, dolutegravir).
32246857	2020	Systematic review / meta-analysis	J Gastroenterol Hepatol	Network meta-analysis of DAA regimen efficacy/safety for HCV in HIV/HCV co-infected patients.
28417245	2017	Review	Drugs	Comprehensive review of elbasvir/grazoprevir for chronic HCV GT1/4.
30233138	2018	Review	Drug Des Devel Ther	Safety and efficacy evidence for elbasvir/grazoprevir in HCV.
27603877	2016	Review	Expert Rev Clin Pharmacol	MOA, PK/PD, efficacy and safety review of elbasvir/grazoprevir for HCV GT1/4.
26849059	2016	Review	Expert Opin Drug Metab Toxicol	Pharmacodynamics/pharmacokinetics of elbasvir and grazoprevir in HCV treatment.

None of the literature above evaluates grazoprevir as an anti-HIV agent — the DDI/PK papers characterize how to safely combine grazoprevir with antiretrovirals when treating HCV in HIV-positive patients, not anti-HIV efficacy of grazoprevir itself.

Taiwan Market Information

Grazoprevir (and the Zepatier® combination) is not currently marketed in Taiwan — 0 registered authorizations, no dosage forms recorded. This means no local regulatory or safety-label information is available to review.

Safety Considerations

Structured safety data (key warnings, contraindications, DDI database) were not available for this candidate. However, the literature evidence pack does contain sourced pharmacokinetic interaction data relevant to any future HIV-related use:

Drug Interactions (from literature, not structured DDI data): Elbasvir/grazoprevir shows clinically significant pharmacokinetic interactions with ritonavir-boosted HIV protease inhibitors (ritonavir, atazanavir, lopinavir, darunavir) and with HIV integrase inhibitors (raltegravir, dolutegravir) (PMID 30745392, 30541077). These interactions matter for HIV/HCV co-infected patients receiving both drug classes concurrently, but do not indicate anti-HIV activity of grazoprevir.

For all other safety information, please refer to the package insert once formally reviewed by TFDA.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score (99.73%) is not corroborated by any trial or literature evidence of grazoprevir treating HIV directly. All 10+ trials and 20 literature records identified are HCV-treatment studies conducted in HIV/HCV co-infected populations — a classic co-occurrence confound in knowledge-graph models. There is no known or plausible molecular mechanism (grazoprevir targets HCV NS3/4A protease; HIV depends on protease/reverse transcriptase/integrase from an unrelated retroviral family) supporting anti-HIV activity. Grazoprevir is also not currently marketed in Taiwan.

To proceed, the following is needed (before this can be considered anything other than Hold):

In vitro assay data confirming (or refuting) grazoprevir activity against HIV protease, reverse transcriptase, or integrase
Formal DrugBank/TFDA MOA and label documentation (currently a data gap)
If in vitro signal is negative (expected), this candidate should be closed rather than advanced

Note on other ranked predictions in this pack: Ranks 2–10 (HBV, HEV, HAV, animal hepatitis, Omsk hemorrhagic fever, SIV, FIV, a rare neurodevelopmental disorder) were also reviewed and show the same or weaker pattern — all scored "Hold" (L5, no genuine mechanistic or clinical support), except rank 7 (Kyasanur forest disease), which was flagged as a low-priority research question based on one in-silico docking study (PMID 34662258) exploiting cross-genus Flaviviridae NS3 protease conservation — still requiring wet-lab validation before any further action.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.